Drug Profile

Research programme: mRNA based immunotheraputics - eTheRNA immunotherapeutics

Alternative Names: mRNA immunotheraputics -eTheRNA Immunotherapies; Triplet-eTheRNA Immunotherapies

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator eTheRNA Immunotherapies
Class Antineoplastics; RNA
Mechanism of Action 4-1BB ligand expression modulators; Interleukin-21 expression modulators; Interleukin-7 expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

10 Dec 2024 Research programme: mRNA based immunotheraputics - eTheRNA immunotherapeutics is available for licensing as of 10 Dec 2024. https://www.etherna.be/partnering/product-partnering/
10 Dec 2024 Preclinical trials in Cancer in Belgium (Intratumoural)
10 Dec 2024 Pharmacodynamics data from a preclinical study in Cancer released by eTheRNA Immunotherapies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com